{
    "id": 20825,
    "fullName": "CXCR4 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CXCR4 positive indicates the presence of the CXCR4 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7852,
        "geneSymbol": "CXCR4",
        "terms": [
            "CXCR4",
            "CD184",
            "D2S201E",
            "FB22",
            "HM89",
            "HSY3RR",
            "LAP-3",
            "LAP3",
            "LCR1",
            "LESTR",
            "NPY3R",
            "NPYR",
            "NPYRL",
            "NPYY3R",
            "WHIM",
            "WHIMS"
        ]
    },
    "variant": "positive",
    "createDate": "04/07/2016",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8781,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of LY2510924 to Sutent (sunitinib) demonstrated safety, but did not improve meidan progression-free survival (8.1 vs 12.3 months) compared to Sutent (sunitinib) alone in renal cell carcinoma patients, regardless of Cxcr4 expression level (PMID: 27154357).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 4810,
                "therapyName": "LY2510924 + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6748,
                    "pubMedId": 27154357,
                    "title": "A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27154357"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11644,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Bendamustine and PF-06747143 resulted in improved efficacy and survival in a chronic lymphocytic leukemia cell line xenograft model compared to PF-06747143 alone (PMID: 28526063).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 6088,
                "therapyName": "Bendamustine + PF-06747143",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9680,
                    "pubMedId": 28526063,
                    "title": "Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28526063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5644,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, POL5551 inhibited migration of breast cancer cells in culture and reduced metastasis in cell line xenograft models, but did not inhibit tumor growth (PMID: 26269605).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 3914,
                "therapyName": "POL5551",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5132,
                    "pubMedId": 26269605,
                    "title": "CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26269605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5645,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of POL5551 and eribulin resulted in reduced metastatic tumor burden and improved survival of breast cancer cell line xenograft models compared to eribulin alone (PMID: 26269605).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 3915,
                "therapyName": "Eribulin + POL5551",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5132,
                    "pubMedId": 26269605,
                    "title": "CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26269605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11130,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of POL6326 plus Halaven (eribulin) in metastatic breast cancer patients with tumors expressing CXCR4 resulted in an objective response rate of 33% (8/24), including 8 patients achieving a partial response, and stable disease in 17% (4/24) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2555)).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 5870,
                "therapyName": "Eribulin + POL6326",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9100,
                    "pubMedId": null,
                    "title": "Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts)",
                    "url": "http://abstracts.asco.org/199/AbstView_199_185772.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11642,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-06747143 induced cell death, led to the activation of reactive oxygen species, and inhibited cell migration of a patient-derived chronic lymphocytic leukemia (CLL) cells in culture, and reduced tumor burden in CLL cell line xenograft models (PMID: 28526063).",
            "molecularProfile": {
                "id": 21324,
                "profileName": "CXCR4 positive"
            },
            "therapy": {
                "id": 6087,
                "therapyName": "PF-06747143",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9680,
                    "pubMedId": 28526063,
                    "title": "Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28526063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21324,
            "profileName": "CXCR4 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}